Published in Ann Gastroenterol on January 01, 2013
Establishing medical plausibility in the context of orphan medicines designation in the European Union. Orphanet J Rare Dis (2014) 1.54
Host cell mTORC1 is required for HCV RNA replication. Gut (2015) 0.88
Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol (2015) 0.76
Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol (2015) 0.75
Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation. Braz J Med Biol Res (2017) 0.75
A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host. Virol J (2016) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis (2001) 2.98
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology (2011) 2.95
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol (2008) 2.63
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology (2002) 2.37
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol (2008) 2.33
Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology (2011) 2.25
Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Increasing burden of liver disease in patients with HIV infection. Lancet (2011) 1.98
Long-term survival after retransplantation of the liver. Ann Surg (1997) 1.91
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant (2008) 1.86
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol (2006) 1.86
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology (2005) 1.82
Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl (2009) 1.76
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology (1999) 1.76
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology (2000) 1.72
Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant (2008) 1.70
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
Trends and experiences in liver retransplantation over 15 years. Liver Transpl (2007) 1.66
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology (2012) 1.64
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant (2013) 1.58
Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl (2007) 1.54
Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl (2012) 1.53
Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl (2003) 1.52
Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl (2005) 1.48
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (2008) 1.47
Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. Liver Transpl (2009) 1.44
Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl (2004) 1.42
[Liver retransplantation: outcome analysis in 50 patients]. Med Clin (Barc) (2005) 1.40
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl (2008) 1.27
Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant (2006) 1.26
The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl (2003) 1.26
Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant (2012) 1.22
Hepatic Retransplantation--an analysis of risk factors associated with outcome. Transplantation (1996) 1.22
Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg (2002) 1.22
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant (2006) 1.20
Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl (2003) 1.19
Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol (2012) 1.18
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat (2008) 1.11
Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology (2010) 1.10
Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol (2006) 1.09
Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl (2012) 1.08
The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation (2012) 1.08
Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant (2011) 1.07
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant (2005) 1.06
Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg (2002) 1.05
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl (2012) 1.05
A simple model to estimate survival after retransplantation of the liver. Transplantation (1999) 1.02
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01
Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation (2009) 1.00
A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl (2007) 0.99
Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection. Am J Transplant (2008) 0.97
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl (2004) 0.96
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology (2004) 0.96
A model to predict survival following liver retransplantation. Hepatology (1999) 0.95
Liver transplantation in HIV-infected recipients. Liver Transpl (2005) 0.93
Clinical characteristics affecting the outcome of liver retransplantation. Transplantation (1997) 0.93
Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol (2010) 0.93
Validation and refinement of survival models for liver retransplantation. Hepatology (2003) 0.91
Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant (2011) 0.91
Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl (2003) 0.91
Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol (2010) 0.91
Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol (2004) 0.91
Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl (2003) 0.91
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. J Gastroenterol (2012) 0.90
Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology (2009) 0.89
Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev (2010) 0.89
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol (2010) 0.87
Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol (2012) 0.87
Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant (2006) 0.86
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl (2003) 0.85
Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach. Liver Transpl (2013) 0.84
Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource? World J Gastroenterol (2010) 0.83
Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int (2008) 0.83
Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl (2005) 0.82
Results of retransplantation for recurrent hepatitis C. Hepatology (2003) 0.82
Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up. Transplant Proc (2001) 0.81
Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transpl (2011) 0.81
Post-liver transplant survival in hepatitis C patients is improving over time. Liver Transpl (2009) 0.81
Liver retransplantation: a model for determining long-term survival. Transplantation (2006) 0.80
Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl (2003) 0.80
Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl (2003) 0.79
A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis. Transplantation (2012) 0.79
Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. Int J Biostat (2010) 0.79